retatrutide drug test results on a popular unapproved peptide have revealed a concentration double that listed on the label, prompting warnings from health professionals about "enormous" overdose risks. By national health equity reporters Caitlyn What is Retatrutide and How

It belongs to a novel class of agents known as triple agonists, targeting three incretin and metabolic receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor

Researchers exploring its weight-loss mechanism continue uncovering promising metabolic data that supports continued study

Semaglutide's adverse events primarily stem from its effects on gastrointestinal motility and gastric emptying

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials

That does not mean semaglutide is a pharmaceutical aphrodisiac

For the first time, Medicare covers GLP-1 weight loss medications